Int J Angiol. 2008;17(3):149-53. doi: 10.1055/s-0031-1278300.

Custodiol versus Plegisol: A phase 3 multicentre myocardial protection study.

The International journal of angiology : official publication of the International College of Angiology, Inc

Todd L Demmy, J Ernesto Molina, Herb B Ward, Michael E Gorton, Nicholas T Kouchoukos, Richard A Schmaltz, Hani Shennib

PMID: 22477420 PMCID: PMC2727762 DOI: 10.1055/s-0031-1278300

Abstract

BACKGROUND: While considered simple and effective, crystalloid antegrade cardioplegia solutions have had few prospective multicentre comparison trials.

METHODS: A commercial intracellular-type histidine-tryptophan-ketoglutarate (HTK) cardioplegia solution (Custodiol HTK; Köhler Chemie GmbH, Germany) designed for 4 h of protection after a single administration was compared with a standard extracellular multidose product (Plegisol [PL]; Hospira Inc, USA) in an open-label, randomized, prospective seven-institution trial. A total of 136 isolated coronary bypass patients were randomly assigned into two groups and stratified by ejection fraction into categories of 40% or greater (n=118) and 20% to 39% (n=18).

RESULTS: The mean age of the study cohort was 62 years, of which 94% were men. Seventy per cent of patients had Canadian Cardiovascular Society class III angina and 75% had three-vessel disease anatomy. Cross-clamp times were nearly identical for patients in both cardioplegia groups; however, defibrillation was needed less often for patients who were treated with HTK (64% versus 91%, P<0.01). Hospital and intensive care unit stays, creatine kinase isoenzyme MB curves, cardiac outputs, inotrope levels, and deaths or serious adverse events (PL=13, HTK=14) were very similar between groups. Logistic regression showed that myocardial infarction or possible treatment-related adverse events were associated with high cardiac troponin I (cTn-I) levels 6 h after the procedure (P=0.001), and HTK treatment (OR 3.5, P=0.01). The primary study end point (6 h post-ischemia cTn-I) favoured PL (16.7±13.2 μg/L versus 20.3±13.5 μg/L, P=0.01). Patients who underwent circumflex grafting had higher cTn-I levels with HTK (P<0.001) and 48% required reinfusions due to cardiac warming. Longer intervals between doses correlated with high cTn-I levels (P=0.02). HTK provided prolonged protection with low cTn-I release (10 μg/L or less), although this occurred less frequently than with PL (17 versus 27 patients, P=0.06).

CONCLUSIONS: HTK caused more structural protein release and adverse events than PL, even when reinfusion was implemented.

References

1. Basic Res Cardiol. 1982 Jul-Aug;77(4):372-87 - PubMed
2. Thorac Cardiovasc Surg. 1987 Feb;35(1):48-52 - PubMed
3. J Thorac Cardiovasc Surg. 2002 Apr;123(4):742-55 - PubMed
4. Ann Thorac Surg. 1995 May;59(5):1192-4 - PubMed
5. Ann Thorac Surg. 2001 Apr;71(4):1312-9 - PubMed
6. Transplantation. 1997 Jan 27;63(2):262-9 - PubMed
7. J Thorac Cardiovasc Surg. 2004 Dec;128(6):860-5 - PubMed
8. J Card Surg. 1998 Jan;13(1):43-7 - PubMed
9. Thorac Cardiovasc Surg. 1988 Jun;36(3):151-6 - PubMed
10. Thorac Cardiovasc Surg. 1980 Oct;28(5):295-302 - PubMed
11. Br J Anaesth. 2002 Jun;88(6):828-35 - PubMed

Publication Types

• Journal Article